CD8A and neoplasm: BiTEs exemplify this mechanism: their compact architecture favors tumor penetration and they indiscriminately engage CD3+ T-cell subsets—including CD4+, CD8+, and Tregs—thereby circumventing native T-cell receptor (TCR) specificity.